Anemia and Kidney Disease
Researchers examined the roles of hyperuricemia and anemia in all-cause mortality with chronic kidney disease (CKD).
The ERA reviewed phase 3 trials to clarify the mechanism behind HIF-PHi and their role in managing CKD-related anemia.
The FDA approved Vafseo (vadadustat) to treat anemia due to chronic kidney disease (CKD) in adults on dialysis.
SGLT2 inhibitors have benefits for anemia risk but their effectiveness among patients with T2D and CKD stage 1-3 was unclear.
Patients with early chronic kidney disease (CKD) frequently develop anemia.
In multivariate logistic regression analysis, a higher UFR was associated with lower hemoglobin levels.
The primary efficacy end point of interest was the mean change in hemoglobin from baseline over weeks 12 to 16.
Patients with chronic kidney disease (CKD) commonly develop anemia.
Trials included in the analysis compared HIF-PHIs to placebo or to erythropoiesis-stimulating agents (ESA).
Patients receiving maintenance hemodialysis who develop anemia are commonly treated with erythropoiesis-stimulating agents.
Patients with end-stage kidney disease with anemia are commonly treated with recombinant human erythropoietin.
There are associations between anemia in ESKD and increased risk of morbidity and mortality.
Advertisement
Advertisement
